Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by ANALIAS00on Oct 09, 2017 9:08pm
161 Views
Post# 26793007

RE:RE:RE:RE:Above 8$ again

RE:RE:RE:RE:Above 8$ again
Test ?  What test ?  Analyst raised their target by +-$1.00 last week.  Market got tested many times so far on TH.  We already know the market dont trust TH stock.   The stock cant be lower at few weeks from an approval that we all know is comming.     Really it would be interesting to see a shareprice at 8$ or $9 at approval but only if you have a plan not to wait for the first sales numbers.  So for me that believes in Ibalizumab and TH's vendor team in place, there is no test but only a MOMENT OF TRUTH.    If approval comes at or before january 3rd, I am afraid that this MOMENT OF TRUTH will come only in February at the Financial Results Announcement.  In fact there may not be much to say in February so there will be several MOMENT OF TRUTH on 2018.     So what ever level SP is between now and the first moment of truth, I may have to wait until july to have a better idea how far Ibalizumab can bring the stock to.    TH=PATIENCE   :o)     But like my daughters would be saying:   "J'ai une bonne VIBE"    :o)    So lets wait ror approval, lets wait for first sales numbers,lets wait for second waves of numbers, lets enjoy the ride !!
Bullboard Posts